PIN17 ESTIMATING THE LONG-TERM HEALTH AND ECONOMIC IMPACT OF A PROPHYLACTIC CERVICAL CANCERVACCINE ON THE BURDEN OF CERVICAL DISEASE IN ITALY  by Ferko, N et al.
old cohort (13.6 vs. 11.3 years). The incremental costs/LYG and
death avoided were €406 and €4730, respectively. Although the
model was sensitive to variables like proven MRSA percentage
and costs accrued by patients who die, varying these parameters
by 25% the overall conclusions remained the same. CONCLU-
SION: According to this model, Linezolid is cost-effective versus
vancomycin for MRSA suspected-nosocomial pneumonia in
Spain, with and additional cost/LYG and death avoided below
the acceptable threshold.
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OBJECTIVES: To assess clinical effectiveness and costs of
Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in
two divided doses) vs Augmentin® conventional twice-daily
regimen (45/6.4 mg/kg/day in two divided doses) in acute otitis
media treatment in Poland from the public payer (NHF) and
payer (NHF + patient) perspective. METHODS: Systematic
review according to Cochrane Collaboration guidelines and clini-
cal effectiveness analysis according to Polish HTA Guidelines
were performed. Medline (Pubmed) Cochrane and EMBASE
were searched (August 2006). Only RCTs with high credibility
assessment (based on Jadad scale) were included in the systematic
review. Overall costs of treatment were taken into account,
including cost of pharmacotherapy, drug administration, second-
line therapy, complications of otitis media and adverse events.
Sensitivity analysis was performed according to a range of acqui-
sition costs of Augmentin ES® and Augmentin® (20%). All
calculations were performed for 2006 (€1 = PLN3.8). RESULTS:
Randomized head-to-head clinical trial of Augmentin ES® vs
conventional Augmentin® was found and signiﬁcant difference
in clinical cure rate between two drugs was revealed: 84.1% vs
78.8%, respectively; no signiﬁcant differences in safety proﬁle
were found. Cost analysis revealed that savings per patient when
Augmentin ES® is used in place of conventional Augmentin®
were: PLN28.27 (€7.4) (public payer) and PLN27.9 (€7.3)
(payer). Results of clinical and cost analysis proved that conven-
tional Augmentin® therapy is dominated by Augmentin ES®.
The results proved to be robust to variations in the drugs cost
acquired in sensitivity analysis. Savings accompanying clinical
cure of one patient in case of Augmentin ES® used in place of
Augmentin® were: PLN533.4 (€140.3) (public payer perspec-
tive) and PLN526.4) (€138.5) (payer perspective). CONCLU-
SION: Augmentin ES® compared with conventional therapy
brings signiﬁcant savings and is a cost-effective treatment of
acute otitis media in Poland.
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OBJECTIVES: To assess clinical effectiveness and costs of
Augmentin ES® (amoxicillin/clavulanic acid 90/6.4 mg/kg/day in
two divided doses) vs azithromycin (10 mg/kg, day 1; 5 mg/kg/d,
days 2–5) in acute otitis media treatment in Poland from the
public payer (NHF) and payer (NHF + patient) perspective.
METHODS: Systematic review according to Cochrane Collabo-
ration guidelines and clinical effectiveness analysis according to
Polish HTA Guidelines were performed. Medline (Pubmed)
Cochrane and EMBASE were searched (August 2006). Only
RCTs with high credibility assessment (based on Jadad scale)
were included in the systematic review. Overall costs of treatment
were taken into account, including cost of pharmacotherapy,
drug administration, second-line therapy, complications of otitis
media and adverse events. Sensitivity analysis was performed
according to a range of acquisition costs of Augmentin ES® and
azithromycin (+/-20%). All calculations were performed for
2006 (€1 = PLN3.8). RESULTS: Randomized head-to-head clini-
cal trial of Augmentin ES® vs azithromycin was found and
signiﬁcant difference in clinical cure rate between two drugs was
revealed: 90.5% vs 80.9%, respectively; no signiﬁcant differences
in safety proﬁle were found. Cost analysis revealed that savings
per patient when Augmentin ES® is used in place of azithromy-
cin were: PLN49 (€12.9) (public payer) and PLN38.3 PLN
(€10.1) (payer). Results of clinical and cost analysis proved that
azithromycin therapy is dominated by Augmentin ES®. The
results proved to be robust to variations in the drugs cost
acquired in sensitivity analysis. Savings accompanying clinical
cure of one patient in case of Augmentin ES® used in place of
azithromycin were: PLN510.5 (€134.3) (from public payer per-
spective) and PLN399.2 (€105) (payer perspective). CONCLU-
SION: Augmentin ES® compared with azithromyycin therapy
brings signiﬁcant savings and is a cost-effective treatment of
acute otitis media in Poland.
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OBJECTIVES: HPV epidemiology and screening practices vary
considerably between countries and speciﬁc analyses are required
to estimate the impact of prophylactic cervical cancer vaccination.
This study adapted a health economic model to Italy to predict the
clinical and economic impact. METHODS: A Markov model
based upon the natural history of HPV and cervical cancer was
developed to simulate transitions between health states (normal,
HPV, Cervical Intraepithelial Neoplasia stages 1 to 3, Cervical
Cancer (CC) stages 1 to 4, and death) in the presence of speciﬁc
screening programs. Italian data was used to for costs, and
screening and treatment practices, and published clinical data was
used to estimate efﬁcacy against oncogenic HPV types 16, 18, 31,
45. The model was calibrated to Italian epidemiological data
including age-speciﬁc HPV prevalence, prevalence of CIN lesions,
CC incidence and mortality. The cost-effectiveness of vaccination
against HPV for cohorts of different ages was assessed using the
calibrated model. RESULTS: With 100% vaccine coverage, in a
12 year old cohort of females there is estimated to be a 68%
reduction in the prevalence of high-grade precancerous lesions due
to oncogenic HPV, and a 78% and 79% reduction in cervical
cancer cases and deaths, respectively. Vaccination would also
produce substantial reductions in these outcomes for the 18 and
25 year old cohorts, and in the number of screening tests and
treatments required. With 3% discount rates on costs and out-
comes, vaccination is cost effective in cohorts of 12, 18, and 25
year oldswith estimated cost perQALYs of €30,624, €31,078, and
€31,116 respectively. CONCLUSION: The model was success-
fully adapted to represent Italian epidemiological data, screening
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and treatment practices and predicted a substantial long-term
beneﬁt of prophylactic cervical cancer vaccination. The vaccine
may be considered to be cost-effective under a number of assump-
tions and vaccination age groups.
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OBJECTIVES: Oseltamivir has been stockpiled for emerging
threat by new inﬂuenza pandemic. Recent studies report some-
what possibility of the virus emerging resistant to oseltamivir. The
purpose of this study is to evaluate the cost-effectiveness of
oseltamivir for inﬂuenza in Japan with considering the com-
plications and the emergence of oseltamivir-resistant virus.
METHODS: A cost-effectiveness analysis was performed by deci-
sion tree using evidence from the Japanese clinical trial and the
NICE, UK, systematic reviews. The decision tree models a patient
presenting with inﬂuenza likely illness and facing the alternative
treatments: rapid diagnostic testing followed by treatment with
oseltamivir or a comparator which goes with conventional treat-
ments. The decision tree visualized morbidity and mortality with
complications such as ill states needed for antibiotics and hospi-
talization due to pneumonia. The analysis included assessment of
not only directmedical costs but also productivity loss. Costs were
derived from published literature and the statistics in DPC (Diag-
nosis Procedure Combination) system in Japan. RESULTS: Con-
sidering the productivity loss during inﬂuenza and complications,
oseltamivir cost JPY150,703, and the comparator, JPY163,415
per QALY. When the prevalence was in the low range of 10%
through 40%, the dominance of oseltamivir vanished. The incre-
mental cost-effectiveness ratio (ICER) of oseltamivir versus com-
parator was JPY398,571 per QALY. Considering the productivity
loss, however, the ICER for oseltamivir turned to be negative,
simple dominant, JPY-2,345,714 per QALY. Regarding the virus
emerging resistant to the drug, we found the dominance of osel-
tamivir vanish if the emerging rate becomes more than 27%.
Sensitivity analysis also suggested that the emerging rate of the
drug-resistant viruswasmore sensitive in the inﬂuenza peri-season
(prevalence: 40–60%). CONCLUSION: The use of oseltamivir
for inﬂuenza was so far recommended as cost-effectiveness in
Japan. However, the advantage of oseltamivir is affected by both
the prevalence and emerging rate of the oseltamivir-resistant virus.
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OBJECTIVES: HPV vaccination is recommended in Germany
for adolescent girls. The objective of this research was to estimate
for Germany, the cost-effectiveness of a candidate prophylactic
cervical cancer vaccine with potential cross-protection beneﬁts.
METHODS: A Markov model based upon the natural history of
HPV and cervical cancer was developed to simulate transitions
between health states: Normal, HPV, Cervical Intraepithelial
Neoplasia (CIN), Cervical Cancer (CC) stages 1 to 4, and death.
Using a lifetime simulation of 12-year old girls, the model was
adapted for country-speciﬁc epidemiological data: age-speciﬁc
HPV prevalence, HPV type distribution in cervical disease,
prevalence of pre-cancerous lesions, and age-speciﬁc CC inci-
dence and mortality. Country-speciﬁc screening practices and
costs were used with a discount rate of 4% on costs, 1.5% on
outcomes. Published efﬁcacy rates were used for the candidate
vaccine including a potential cross-protection beneﬁt (i.e., addi-
tional efﬁcacy against oncogenic HPV types 31 and 45). Sensi-
tivity analyses were performed on costs, discount rates, efﬁcacies,
cross-protection, and age at vaccination. RESULTS: Reductions
in CC and related deaths were predicted to be 81% (80% mor-
tality) following vaccination of 12 year old girls. The correspond-
ing cost per life-year gained ranged from €19,600 to €20,700
respectively, depending upon whether the analysis was conducted
from a societal or health-care payer perspective. When consider-
ing quality of life beneﬁts, the vaccine showed a cost per quality-
adjusted life-year of €14,700 (societal) to €15,500 (payer).
Results were most sensitive to assumptions about discount rates
and age at vaccination. For cohorts of 18, and 25-year-old
women, vaccination has estimated cost per QALYs of €16,100
and €18,800 (societal), and €15,300 and €18,000 (payer), respec-
tively. CONCLUSION: Prophylactic vaccination against CC
with a candidate HPV 16/18 vaccine is a cost-effective method of
reducing precancerous cervical lesions, cervical cancer incidence
and mortality in Germany.
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OBJECTIVES: This study estimates the cost and the effectiveness
of brivudine and aciclovir in the treatment of Herpes Zoster
(HZ) in Spain focusing on the number of post herpetic neuralgia
(PHN) avoided cases. METHODS: A cost-effectiveness decision
model was built from clinical results obtained in the double-blind
controlled trail that compared brivudine and aciclovir. The ana-
lytic model estimates the mean cost per patient treated with HZ
and the mean cost per PHN avoided case. Time horizon of the
study considered HZ acute treatment period (7 days) plus PHN
treatment period (between 90 and 180 days). This decision
model also considers the incidence rate of HZ in Spain for
patients older than 50 years, clinical drug effectiveness, HZ and
PHN direct medical costs and three PHN treatments options
(tramadol, gabapentine and pregabaline). RESULTS: It has been
estimated that 109.982 patients with HZ would be treated in
Spain each year. If all those patients would be treated with
brivudine, then 8,976 NPH cases could be avoided if the same
number of patients would receive aciclovir. Mean cost per treated
patient would be lower with brivudine for all PHN treatment
options. Overall, brivudine has a greater effectiveness and a
lower cost per treated patient, thus estimated direct medical cost
per PHN avoided case would be reduced in 33€ when the PHN
patient is treated with tramadol, 35€ for gabapentine and 71€ for
pregabaline. CONCLUSION: Results from base-case and sensi-
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